September 2, 2020
Endologix Launches Alto Abdominal Stent Graft System Outside of the United States
September 2, 2020—Endologix, Inc. announced the first commercial implant of its Alto abdominal stent graft system outside of the United States. The procedure was performed by Andrew Holden, MD, and Andrew Hill, MD, of Auckland City Hospital in Auckland, New Zealand.
The company announced CE Mark approval of the Alto endograft for endovascular aneurysm repair in abdominal aortic aneurysms (AAAs) on August 5, 2020. In the United States, the commercial launch of the device was announced on July 30, 2020, after receiving FDA approval in March.
“With the 7-mm infrarenal placement of its sealing ring, Alto expands the endovascular treatment of AAA patients to include short and challenging aortic necks, which represent a significant portion of the underserved AAA market,” commented Dr. Holden in the company’s announcement. “We are excited to add Alto to our endovascular armamentarium and look forward to offering this solution to a broad set of AAA patients.”
Dr. Hill added, “The Alto endograft with its ultra-low-profile delivery system is ideal for treating patients with small vessels and challenging access. The new system provides a unique endovascular option, representing an important advancement for physicians and their AAA patients.”